CoQ10 for Heart Failure: The Q-SYMBIO Study
Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, et al
JACC Heart Failure • December 2014
Plain Language Summary
This 2-year study of 420 heart failure patients found that taking CoQ10 (300mg daily) reduced the risk of dying from heart problems by 43% compared to placebo. Patients also had fewer hospitalizations and improved heart function. CoQ10 was added to standard heart failure medications and was well tolerated. This suggests CoQ10 may be an important addition to conventional heart failure treatment.
Key Findings
- 143% reduction in cardiovascular mortality (HR 0.57, 95% CI 0.37-0.89)
- 242% reduction in all-cause mortality
- 3Significant improvement in NYHA functional class
- 4Reduced heart failure hospitalizations
- 5Well tolerated with minimal side effects
Abstract
The Q-SYMBIO trial was a randomized, double-blind, multicenter trial evaluating CoQ10 supplementation (100mg three times daily) in patients with moderate to severe heart failure receiving standard treatment.
Study Limitations
- Moderate sample size
- Some centers had slow enrollment
- Baseline characteristics slightly unbalanced
- Requires replication in larger trials